EKSO BIONICS HOLDINGS, INC. 8-K

What Happened

• On December 29, 2025, Ekso Bionics Holdings, Inc. (Ekso) announced an exclusive, non‑binding term sheet with Applied Digital Corporation to combine Applied’s cloud computing business (Applied Digital Cloud) with Ekso. The combined business is expected to operate as ChronoScale, an accelerated compute platform focused on AI workloads.
• Under the term sheet, Applied would own approximately 97% of the combined company and Ekso’s current stockholders would hold about 3% (subject to proportional dilution from any equity financing at closing). The Applied Digital Cloud and Ekso businesses will continue to operate until closing, and Ekso said it will continue to explore strategic transactions for a possible sale of all or substantially all of its current business.
• The transaction remains subject to customary due diligence, execution of definitive agreements, regulatory and stockholder approvals, and other closing conditions. Ekso furnished a press release as Exhibit 99.1 to the 8‑K.

Key Details

• Date filed: December 29, 2025 (Form 8‑K).
• Proposed new company name: ChronoScale — an accelerated compute platform for AI workloads.
• Expected ownership post‑close: Applied ~97%; Ekso existing stockholders ~3% (may be diluted by equity financing).
• Next SEC steps: ChronoScale may file a Registration Statement on Form S‑4 (or Ekso may file a standalone proxy); definitive proxy/prospectus will be mailed to Ekso stockholders when available.

Why It Matters

• This is a major strategic shift: the combined business centers on AI/cloud compute rather than Ekso’s historical robotics/exoskeleton business, and Ekso shareholders would own only a small stake in the new company unless further negotiated or financed.
• The deal is at the term‑sheet stage with no guarantee it will close; investors should watch for definitive agreements, the S‑4/proxy filings, and any announcements about Ekso’s plans for its current business.
• Materials and formal disclosures will be filed with the SEC; investors should read the forthcoming proxy/prospectus before making voting or investment decisions.